V. Juneja

Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer

M. Reiss, D. Zelterman, G. Chung, 2007, Breast Cancer Research and Treatment.

Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents in Patients with Cancer

P. Keegan, R. Pazdur, M. Rothmann, 2008, Clinical Cancer Research.

Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation?

Martin R. Johnson, R. Diasio, M. Saif, 2007, Supportive cancer therapy.

Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA – N 2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy †

Ronald, Ramalingam, Igor, 2015 .

Hand-foot syndrome (HFS) in patients treated with capecitabine (CAP) and the role of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD).

R. Diasio, M. Saif, M. Johnson, 2006, Journal of Clinical Oncology.